Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023 · see citing works

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940 · see citing works

Standards of Medical Care in Diabetes–2006

American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s4 · Cited by 1,884 · see citing works

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · see citing works

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · see citing works

Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · see citing works

Reduced incretin effect in Type 2 (non-insulin dependent) diabetes

Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · see citing works

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · see citing works

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.

Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209 · see citing works

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · see citing works

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161 · see citing works

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · see citing works

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · see citing works

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.

Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · see citing works

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.

Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906 · see citing works

Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 876 · see citing works

Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus

Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · see citing works

Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.

Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837 · see citing works

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans

Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R. A., & Schmiegel, W. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 822 · see citing works

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · see citing works

Glucagon-Like Peptide 1 Inhibits Cell Apoptosis and Improves Glucose Responsiveness of Freshly Isolated Human Islets

Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664 · see citing works

Racial and ethnic differences in glycemic control of adults with type 2 diabetes.

Harris, M. I., Eastman, R. C., Cowie, C. C., Flegal, K. M., & Eberhardt, M. S. (1999) · Diabetes Care · doi:10.2337/diacare.22.3.403 · Cited by 643 · see citing works

Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers

Nauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605 · see citing works

A Meta-Analysis of the Effect of Glucagon-Like Peptide-1 (7–36) Amide on Ad Libitum Energy Intake in Humans

Verdich, C., Flint, A., Gutzwiller, J., Näslund, E. B., Beglinger, C., Hellström, P. M., Long, S. J., Morgan, L., Holst, J. J., & Astrup, A. V. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7877 · Cited by 600 · see citing works

Exon duplication and divergence in the human preproglucagon gene

Bell, G. I., Sanchez-Pescador, R., Laybourn, P. J., & Najarian, R. C. (1983) · Nature · doi:10.1038/304368a0 · Cited by 593 · see citing works

Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis

Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589 · see citing works

The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion

Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582 · see citing works

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 576 · see citing works

Cloning and Functional Expression of the Human Islet GLP-1 Receptor: Demonstration That Exendin-4 Is an Agonist and Exendin-(9–39) an Antagonist of the Receptor

Thorens, B., Porret, A., Bühler, L. H., Deng, S., Morel, P., & Widmann, C. (1993) · Diabetes · doi:10.2337/diab.42.11.1678 · Cited by 552 · see citing works

Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes

Kolterman, O., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D. S., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 549 · see citing works

Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2

Gutzwiller, J., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1541 · Cited by 521 · see citing works

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

Nauck, M. A., Bartels, E., Ørskov, C., Ebert, R., & Creutzfeldt, W. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.4.8473405 · Cited by 505 · see citing works

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502 · see citing works

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

Edwards, C. M. B., Stanley, S. A., Davis, R. P., Brynes, A. E., Frost, G. S., Seal, L., Ghatei, M. A., & Bloom, S. R. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.1.e155 · Cited by 464 · see citing works

Postprandial Blood Glucose

Association, A. D. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.775 · Cited by 464 · see citing works

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

Nielsen, L. L., Young, A. A., & Parkes, D. G. (2003) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.028 · Cited by 455 · see citing works

Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects

Vilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444 · see citing works

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus

Kolterman, O., Kim, D. D. H., Shen, L. Z., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434 · see citing works

Minireview: The Glucagon-Like Peptides

Drucker, D. J. (2001) · Endocrinology · doi:10.1210/endo.142.2.7983 · Cited by 421 · see citing works

Glucagon-Like Peptide-1 and Exendin-4 Stimulate β-Cell Neogenesis in Streptozotocin-Treated Newborn Rats Resulting in Persistently Improved Glucose Homeostasis at Adult Age

Tourrel‐Cuzin, C., Bailbé, D., Meile, M.-J., Kergoat, M., & Portha, B. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1562 · Cited by 361 · see citing works

Effect on Glycemic Control of Exenatide (Synthetic Exendin-4) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients With Type 2 Diabetes

Fineman, M. S., Bicsak, T. A., Shen, L. Z., Taylor, K., Gaines, E., Varns, A., Kim, D. S., & Baron, A. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2370 · Cited by 353 · see citing works

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (1999) · Diabetes Care · doi:10.2337/diacare.22.7.1137 · Cited by 339 · see citing works

Glucagon-like peptide-1 prevents beta cell glucolipotoxicity

Joly, E. C., Prentki, M., Buteau, J., El-Assaad, W., Rhodes, C. J., & Rosenberg, L. (2004) · Diabetologia · doi:10.1007/s00125-004-1379-6 · Cited by 337 · see citing works

Documentation of Hyperglucagonemia Throughout the Day in Nonobese and Obese Patients with Noninsulin-Dependent Diabetes Mellitus*

REAVEN, G. M., CHEN, Y.-D. I., GOLAY, A., SWISLOCKI, A. L. M., & JASPAN, J. B. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-1-106 · Cited by 326 · see citing works

Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells.

Zhou, J., Wang, X., Piñeyro, M. A., & Egan, J. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2358 · Cited by 319 · see citing works

Insulinotropic Hormone Glucagon-Like Peptide-1 Differentiation of Human Pancreatic Islet-Derived Progenitor Cells into Insulin-Producing Cells

Abraham, E. J., Leech, C. A., Lin, J. C., Zulewski, H., & Habener, J. F. (2002) · Endocrinology · doi:10.1210/endo.143.8.8973 · Cited by 310 · see citing works

The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7–37) in normal and diabetic subjects

Elahi, D., McAloon-Dyke, M., Fukagawa, N. K., Meneilly, G. S., Sclater, A. L., Minaker, K. L., Habener, J. F., & Andersen, D. K. (1994) · Regulatory Peptides · doi:10.1016/0167-0115(94)90136-8 · Cited by 308 · see citing works

Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats

Szayna, M., Doyle, M. E., Betkey, J. A., Holloway, H. W., Spencer, R. G. S., Greig, N. H., & Egan, J. M. (2000) · Endocrinology · doi:10.1210/endo.141.6.7490 · Cited by 303 · see citing works

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes

Fehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1093 · Cited by 297 · see citing works

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM

Rachman, J., Barrow, B. A., Lévy, J., & Turner, R. C. (1997) · Diabetologia · doi:10.1007/s001250050664 · Cited by 265 · see citing works

The Insulinotropic Effect of Acute Exendin-4 Administered to Humans: Comparison of Nondiabetic State to Type 2 Diabetes

Egan, J. M., Clocquet, A. R., & Elahi, D. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8337 · Cited by 247 · see citing works

Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro

Parkes, D. G., Pittner, R. A., Jodka, C. M., Smith, P., & Young, A. J. (2001) · Metabolism · doi:10.1053/meta.2001.22519 · Cited by 241 · see citing works

Exenatide (Exendin-4) Improves Insulin Sensitivity and β-Cell Mass in Insulin-Resistant Obesefa/faZucker Rats Independent of Glycemia and Body Weight

Gedulin, B. R., Nikoulina, S. E., Smith, P. A., Gedulin, G., Nielsen, L. L., Baron, A., Parkes, D. G., & Young, A. A. (2004) · Endocrinology · doi:10.1210/en.2004-1349 · Cited by 241 · see citing works

Physiological Importance of Deficiency in Early Prandial Insulin Secretion in Non-Insulin-Dependent Diabetes

Bruce, D. G., Chisholm, D. J., Storlien, L. H., & Kraegen, E. W. (1988) · Diabetes · doi:10.2337/diab.37.6.736 · Cited by 232 · see citing works

Effectiveness of progressive dose‐escalation of exenatide (exendin‐4) in reducing dose‐limiting side effects in subjects with type 2 diabetes

Fineman, M. S., Shen, L. Z., Taylor, K., Kim, D. D. H., & Baron, A. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.499 · Cited by 227 · see citing works

Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships

Ritzel, R. A., �rskov, C., Holst, J. J., & Nauck, M. A. (1995) · Diabetologia · doi:10.1007/bf00401846 · Cited by 210 · see citing works

Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and Treatment

Mahler, R. J., & Adler, M. L. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.4.5612 · Cited by 206 · see citing works

Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

Mannucci, E., Pala, L., Ciani, S., Bardini, G., Pezzatini, A., Sposato, I., Cremasco, F., Ognibene, A., & Rotella, C. M. (2005) · Diabetologia · doi:10.1007/s00125-005-1749-8 · Cited by 206 · see citing works

Structure-Function of the Glucagon Receptor Family of G Protein-Coupled Receptors: The Glucagon, GIP, GLP-1, and GLP-2 Receptors

Brubaker, P. L., & Drucker, D. J. (2002) · Receptors and Channels · doi:10.3109/10606820213687 · Cited by 198 · see citing works

Dose—Response Relationships

Hartung, R. (1987) · Springer eBooks · doi:10.1007/978-1-4684-5290-7_3 · Cited by 176 · see citing works

Role of Endogenous Glucagon-Like Peptide-1 in Islet Regeneration After Partial Pancreatectomy

León, D. D. D., Deng, S., Madani, R., Ahima, R. S., Drucker, D. J., & Stoffers, D. A. (2003) · Diabetes · doi:10.2337/diabetes.52.2.365 · Cited by 172 · see citing works

Tissue-specific Expression of Unique mRNAs That Encode Proglucagon-derived Peptides or Exendin 4 in the Lizard

Chen, Y. E., & Drucker, D. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4108 · Cited by 167 · see citing works

Determinants of the Effectiveness of Glucagon-Like Peptide-1 in Type 2 Diabetes

Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7743 · Cited by 164 · see citing works

Pharmacokinetic actions of exendin‐4 in the rat: Comparison with glucagon‐like peptide‐1

Parkes, D. G., Jodka, C. M., Smith, P., Nayak, S., Rinehart, L., Gingerich, R., Chen, K. S., & Young, A. J. (2001) · Drug Development Research · doi:10.1002/ddr.1195 · Cited by 158 · see citing works

Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1

Holst, J. J. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.328 · Cited by 155 · see citing works

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

Gutniak, M., Linde, B., Holst, J. J., & Efendić, S. (1994) · Diabetes Care · doi:10.2337/diacare.17.9.1039 · Cited by 139 · see citing works

Rapid gastric emptying of an oral glucose solution in type 2 diabetic patients.

Phillips, W. T., Schwartz, J. G., & McMahan, C. A. (1992) · PubMed · Cited by 135 · see citing works

Contribution to Postprandial Hyperglycemia and Effect on Initial Splanchnic Glucose Clearance of Hepatic Glucose Cycling in Glucose-Intolerant or NIDDM Patients

Butler, P. C., & Rizza, R. A. (1991) · Diabetes · doi:10.2337/diab.40.1.73 · Cited by 127 · see citing works

Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4.

Raufman, J., Singh, L., Singh, G., & Eng, J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36628-1 · Cited by 122 · see citing works

Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action

Egan, J. M., Montrose‐Rafizadeh, C., Wang, Y., Bernier, M., & Roth, J. (1994) · Endocrinology · doi:10.1210/endo.135.5.7956929 · Cited by 121 · see citing works

Glucagon-Like Peptide-1 Augments Insulin-Mediated Glucose Uptake in the Obese State

Egan, J. M., Meneilly, G. S., Habener, J. F., & Elahi, D. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.8.8743 · Cited by 119 · see citing works

Glucagon-Like Peptide-I and the Control of Insulin Secretion in the Normal State and in NIDDM

Thorens, B., & Waeber, G. (1993) · Diabetes · doi:10.2337/diab.42.9.1219 · Cited by 116 · see citing works

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

Nauck, M. A., Sauerwald, A., Ritzel, R. A., Holst, J. J., & Schmiegel, W. (1998) · Diabetes Care · doi:10.2337/diacare.21.11.1925 · Cited by 113 · see citing works

Glucagon‐like peptide (GLP)‐1 and leptin concentrations in obese patients with Type 2 diabetes mellitus

Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Fanelli, A., Messeri, G., & Rotella, C. M. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00367.x · Cited by 106 · see citing works

Stimulation of Release of Insulin by an Extract of Intestinal Mucosa

Dupré, J., & Beck, J. C. (1966) · Diabetes · doi:10.2337/diab.15.8.555 · Cited by 96 · see citing works

A randomized, open-label, crossover study examiningthe effect of injection site on bioavailability of exenatide (synthetic exendin-4)

Calara, F. B., Taylor, K., Han, J., Zabala, E., Carr, E. M., Wintle, M. E., & Fineman, M. S. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.02.008 · Cited by 94 · see citing works

Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice

Ling, Z., Wu, D., Zambre, Y., Flamez, D., Drucker, D. J., PIPELEERS, D. G., & Schuit, F. C. (2001) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280000374 · Cited by 91 · see citing works

Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes

Egan, J. M., Meneilly, G. S., & Elahi, D. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00315.2002 · Cited by 82 · see citing works

Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects

EDWARDS, C. M. B., TODD, J. F., Ghatei, M. A., & Bloom, S. R. (1998) · Clinical Science · doi:10.1042/cs0950719 · Cited by 57 · see citing works

Effect of Glucagon-Like Peptide-1(7-36)-Amide on Initial Splanchnic Glucose Uptake and Insulin Action in Humans With Type 1 Diabetes

Vella, A. V., Shah, P., Basu, R., Basu, A., Camilleri, M., Schwenk, F. W., Holst, J. J., & Rizza, R. A. (2001) · Diabetes · doi:10.2337/diabetes.50.3.565 · Cited by 48 · see citing works

Induction of Gαq-specific Antisense RNA in Vivo Causes Increased Body Mass and Hyperadiposity

Galvin‐Parton, P., Chen, X., Moxham, C. M., & Malbon, C. C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4335 · Cited by 33 · see citing works

Exendin-4, a GLP-1 receptor agonist, stimulates pituitary-adrenocortical axis in the rat: Investigations into the mechanism(s) underlying Ex4 effect

Malendowicz, L., Nussdorfer, G., Nowak, K., Ziolkowska, A., Tortorella, C., & Trejter, M. (2003) · International Journal of Molecular Medicine · doi:10.3892/ijmm.12.2.237 · Cited by 28 · see citing works

Insulin Resistance and Insulin Resistance Syndrome

(2013) · CRC Press eBooks · doi:10.3109/9780203217412 · Cited by 26 · see citing works

Regulation of net hepatic glucose uptake: interaction of neural and pancreatic mechanisms

Moore, M., & Cherrington, A. (1996) · annales de biologie animale biochimie biophysique · doi:10.1051/rnd:19960406 · Cited by 18 · see citing works

D-chiro-inositol and Insulin Resistance: An Allosteric Point of View

Larner, J. (2013) · CRC Press eBooks · doi:10.3109/9780203217412-17 · Cited by 11 · see citing works

Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models

Zhang, H., Wu, C., Chen, Q., Chen, X., Xu, Z., Wu, J., & Cai, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061477 · Cited by 224 · see citing works

Progress in Structure Based Drug Design for G Protein-Coupled Receptors

Congreve, M., LANGMEAD, C. J., Mason, J. S., & Marshall, F. H. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200371q · Cited by 213 · see citing works

Caudal Brainstem Processing Is Sufficient for Behavioral, Sympathetic, and Parasympathetic Responses Driven by Peripheral and Hindbrain Glucagon-Like-Peptide-1 Receptor Stimulation

Hayes, M. R., Skibicka, K. P., & Grill, H. J. (2008) · Endocrinology · doi:10.1210/en.2007-1743 · Cited by 214 · see citing works

Guideline for management of postmeal glucose

Ceriello, A., Colagiuri, S., Gerich, J. E., & Tuomilehto, J. O. (2008) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.01.012 · Cited by 208 · see citing works

The nucleus tractus solitarius: a portal for visceral afferent signal processing, energy status assessment and integration of their combined effects on food intake

Grill, H. J., & Hayes, M. R. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.10 · Cited by 174 · see citing works

Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells

Ding, L., & Jin, Z. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.149 · Cited by 147 · see citing works

New Drugs for Type 2 Diabetes Mellitus

Krentz, A. J., Patel, M., & Bailey, C. J. (2008) · Drugs · doi:10.2165/00003495-200868150-00005 · Cited by 121 · see citing works

DPP-4 Inhibition and the Path to Clinical Proof

Åhrén, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00376 · Cited by 121 · see citing works

Selective tissue targeting of synthetic nucleic acid drugs

Seth, P. P., Tanowitz, M., & Bennett, C. F. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125228 · Cited by 109 · see citing works

Exendin-4 attenuates neuronal death via GLP-1R/PI3K/Akt pathway in early brain injury after subarachnoid hemorrhage in rats

Xie, Z., Enkhjargal, B., Wu, L., Zhou, K., Sun, C., Hu, X., Gospodarev, V. V., Tang, J., You, C., & Zhang, J. H. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.040 · Cited by 97 · see citing works

Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management

Gutierrez, A., & Balasubramanyam, A. (2011) · Endocrine · doi:10.1007/s12020-011-9565-z · Cited by 82 · see citing works

Design, Synthesis, and Biological Activity of Novel Dicoumarol Glucagon-like Peptide 1 Conjugates

Han, J. D. J., Sun, L., Chu, Y., Li, Z., Huang, D., Zhu, X., Qian, H., & Huang, W. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4017448 · Cited by 70 · see citing works

Development of a Highly Visual, Simple, and Rapid Test for the Discovery of Novel Insulin Mimetics in Living Vertebrates

Lee, J., Jung, D., Kim, W., Um, J., Yim, S., Oh, W. K., & Williams, D. R. (2013) · ACS Chemical Biology · doi:10.1021/cb4000162 · Cited by 59 · see citing works

The incretin hormone glucagon‐like peptide 1 increases mitral cell excitability by decreasing conductance of a voltage‐dependent potassium channel

Thiebaud, N., Llewellyn‐Smith, I. J., Gribble, F. M., Reimann, F. M., Trapp, S., & Fadool, D. A. (2016) · The Journal of Physiology · doi:10.1113/jp272322 · Cited by 57 · see citing works

Molecular imaging of β-cells: diabetes and beyond

Wei, W., Ehlerding, E. B., Lan, X., Luo, Q., & Cai, W. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.022 · Cited by 51 · see citing works

Acute effects of an oral supplement of (–)-epicatechin on postprandial fat and carbohydrate metabolism in normal and overweight subjects

Gutiérrez-Salmeán, G., Ortiz-Vilchis, P., Vacaseydel, C. M., Rubio-Gayosso, I., Meaney, E., Villarreal, F., Ramírez-Sánchez, I., & Ceballos, G. (2014) · Food & Function · doi:10.1039/c3fo60416k · Cited by 51 · see citing works

Hypoglycemic effect of Chlorella vulgaris intake in type 2 diabetic Goto-Kakizaki and normal Wistar rats

Jeong, H., Kwon, H. J., & Kim, M. K. (2009) · Nutrition Research and Practice · doi:10.4162/nrp.2009.3.1.23 · Cited by 50 · see citing works

Positron emission tomography imaging of the glucagon-like peptide-1 receptor in healthy and streptozotocin-induced diabetic pigs

Nalin, L., Selvaraju, R. K., Velikyan, I., Berglund, M., Andréasson, S., Wikstrand, A., Rydén, A., Lubberink, M., KANDEEL, F. R., Nyman, G. C., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2745-3 · Cited by 48 · see citing works

Diabetes mellitus and gastric emptying: questions and issues in clinical practice

Samsom, M., Bharucha, A. E., Gerich, J. E., Herrmann, K., Limmer, J., Linke, R., Maggs, D. G., Schirra, J. R. J., Vella, A. V., Wörle, H., et al. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.974 · Cited by 47 · see citing works

Diminished Phosphodiesterase-8B Potentiates Biphasic Insulin Response to Glucose

Dov, A., Abramovitch, E., Warwar, N., & Nesher, R. (2007) · Endocrinology · doi:10.1210/en.2007-0968 · Cited by 48 · see citing works

Novel fatty chain-modified glucagon-like peptide-1 conjugates with enhanced stability and prolonged in vivo activity

Han, J. D. J., Huang, X., Sun, L., Li, Z., Qian, H., & Huang, W. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.05.012 · Cited by 47 · see citing works

A new horizon: oxytocin as a novel therapeutic option for obesity and diabetes

Cai, D., & Purkayastha, S. (2013) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2013.05.006 · Cited by 38 · see citing works

Liraglutide-loaded poly(lactic-co-glycolic acid) microspheres: Preparation and in vivo evaluation

Wu, J., Williams, G. R., Branford‐White, C., Li, H., Li, Y., & Zhu, L. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.06.018 · Cited by 36 · see citing works

Pre-clinical evaluation of [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 for imaging of insulinoma

Selvaraju, R. K., Velikyan, I., Asplund, V., Johansson, L., Wu, Z., Todorov, I., Shively, J. E., KANDEEL, F. R., Eriksson, B. K., Korsgren, O., et al. (2014) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2014.03.017 · Cited by 34 · see citing works

GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1

Li, Y., Zheng, X., Tang, L., Xu, W., & Gong, M. (2011) · Peptides · doi:10.1016/j.peptides.2011.04.001 · Cited by 33 · see citing works

Acidic Nanoparticles Restore Lysosomal Acidification and Rescue Metabolic Dysfunction in Pancreatic β-Cells under Lipotoxic Conditions

Lo, C. H., O’Connor, L. M., Loi, G. W. Z., Saipuljumri, E. N., Indajang, J., Lopes, K. M., Shirihai, O. S., Grinstaff, M. W., & Zeng, J. (2024) · ACS Nano · doi:10.1021/acsnano.3c09206 · Cited by 33 · see citing works

Design and Synthesis of Diazatricyclodecane Agonists of the G‑Protein-Coupled Receptor 119

Darout, E., Robinson, R. P., McClure, K. F., Corbett, M. S., Li, B., Shavnya, A., Andrews, M. P., Jones, C. S., Qifang, L., Minich, M. L., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301626p · Cited by 31 · see citing works

Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications

Giannoukakis, N. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.4.575 · Cited by 30 · see citing works

Synthesis of β- and γ-Hydroxy α-Amino Acids via Enzymatic Kinetic Resolution and Cyanate-to-Isocyanate Rearrangement

Szcześniak, P., Październiok-Holewa, A., Klimczak, U., & Stecko, S. (2014) · The Journal of Organic Chemistry · doi:10.1021/jo502026a · Cited by 29 · see citing works

Exendin-4 Preserves Blood-Brain Barrier Integrity via Glucagon-Like Peptide 1 Receptor/Activated Protein Kinase-Dependent Nuclear Factor-Kappa B/Matrix Metalloproteinase-9 Inhibition After Subarachnoid Hemorrhage in Rat

Xie, Z., Enkhjargal, B., Matei, N., Wu, L., Zhu, Q., Zhang, T., Tang, J., & Zhang, J. H. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.750726 · Cited by 24 · see citing works

Disulfide bond prolongs the half-life of therapeutic peptide-GLP-1

Li, Y., Li, X., Zheng, X., Tang, L., Xu, W., & Gong, M. (2011) · Peptides · doi:10.1016/j.peptides.2011.05.003 · Cited by 20 · see citing works

Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact

Lee, A. A., Khotina, V. A., Kashirskikh, D. A., Voronko, O. E., Gasanov, V. A. O., & Vasiliev, A. V. (2025) · Medical Sciences · doi:10.3390/medsci13040269 · Cited by 16 · see citing works

Long-Acting GLP-1 Analogue in V-Shaped Conformation by Terminal Polylysine Modifications

Yang, X., Li, Y., Wang, Y., Zheng, X., Kong, W., Meng, F., Zhou, Z., Liu, C., Li, Y., & Gong, M. (2014) · Molecular Pharmaceutics · doi:10.1021/mp5002685 · Cited by 17 · see citing works

Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study

Wang, J., Huang, J., Li, W., Tang, S., Sun, J., Zhang, X., Liu, J., Yi, B., Liu, J., Zhang, X., et al. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14091 · Cited by 16 · see citing works

Self-Assembling Peptides Improve the Stability of Glucagon-like Peptide-1 by Forming a Stable and Sustained Complex

Li, Y., Shao, M., Zheng, X., Kong, W., Zhang, J., & Gong, M. (2013) · Molecular Pharmaceutics · doi:10.1021/mp4001734 · Cited by 15 · see citing works

Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy

Lage, M. J., Fabunmi, R. P., Boye, K. S., & Misurski, D. A. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0002-0 · Cited by 14 · see citing works

Some Common Antidiabetic Plants of the Indian Subcontinent

Thakur, G., Pal, K., Mitra, A., Mukherjee, S., Basak, A., & Rousseau, D. (2010) · Food Reviews International · doi:10.1080/87559129.2010.496024 · Cited by 11 · see citing works

Hyperglycemic and Hypoglycemic Drugs

Vardanyan, R., & Hruby, V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-411492-0.00026-2 · Cited by 8 · see citing works

Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review

Machado, M. F., Shunk, T., Hansen, G., Harvey, C., Fulford, B., Hauf, S., Schuh, O., Kaldas, M., Arcaroli, E., Ortiz, J. P., et al. (2024) · Cureus · doi:10.7759/cureus.66691 · Cited by 7 · see citing works

A new perspective of probe development for imaging pancreatic beta cell in vivo.

Neo, C. W. Y., Ciaramicoli, L. M., Soetedjo, A. A. P., Teo, A., & Kang, N.-Y. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.01.009 · Cited by 8 · see citing works

Modulated approaches for strategic transportation of proteins and peptides via ocular route

Bhatt, M., & Shende, P. K. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102835 · Cited by 7 · see citing works

Preparation of [177Lu]Lu-DOTA-Ahx-Lys40-Exendin-4 for radiotherapy of insulinoma: a detailed insight into the radiochemical intricacies

Guleria, M., Das, T., Amirdhanayagam, J., Sarma, H. D., & Dash, A. K. (2019) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2019.11.003 · Cited by 7 · see citing works

Application of novel peptide (Pp1) improving the half-life of exendin-4 in vivo

Zheng, X., Li, Y., Fu, G., & Gong, M. (2011) · Peptides · doi:10.1016/j.peptides.2011.02.009 · Cited by 7 · see citing works

The role of incretin on diabetes mellitus.

Sanusi, H. D. (2009) · PubMed · Cited by 7 · see citing works

Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial

Wang, L., Liu, X.-Y., Yang, W., Lai, J.-B., Yu, X., Liu, J.-R., Gao, X., Jie, M., Ma, K.-Y., Xu, J., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00904-z · Cited by 6 · see citing works

Bridging Between Disease, Prevalence and Treatment of Diabetes Mellitus : A Review

Swain, R. P., Subudhi, B. B., & Mahapatra, A. K. (2015) · Cited by 5 · see citing works

A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo

Li, Y., Xu, W., Tang, L., Gong, M., & Zhang, J. (2011) · Peptides · doi:10.1016/j.peptides.2011.05.026 · Cited by 5 · see citing works

Chemogenetic inhibition of the lateral hypothalamus effectively reduces food intake in rats in a translational proof-of-concept study

Kovács, P., Kitka, T., Bali, Z. K., Nagy, L. V., Bodó, A., Kovács‐Öller, T., Péterfi, Z., & Hernádi, I. (2024) · Scientific Reports · doi:10.1038/s41598-024-62014-1 · Cited by 3 · see citing works

Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus

Wang, Y., Xu, B., Zhu, L., Lou, K., Chen, Y., Zhao, X., Wang, Q., Xu, L., Guo, X., Ji, L., et al. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0569-1 · Cited by 3 · see citing works

Novel Modified GLP-1 Derivatives with Prolonged Glucose-Lowering Ability In Vivo

Liu, Y., Wang, Q., Nie, D., Zhang, Y., Wang, Z., & Zhang, Y. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09991-4 · Cited by 2 · see citing works

Effects of Exenatide plus Metformin versus Metformin alone on insulin resistance in women with Polycystic Ovary Syndrome: A systematic review and meta‐analysis

Al-Qudah, A.-A., Al‐Hanaktah, M., & Albadaineh, R. (2025) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.16296 · Cited by 2 · see citing works

Formation of cyclic structure at amino-terminus of glucagon-like peptide-1 exhibited a prolonged half-life in vivo

Cao, Z., Li, Y., Tang, L., Xu, W., Liu, C., Zhang, J., & Gong, M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.01.010 · Cited by 2 · see citing works

Treatment of type 2 diabetes

Nazarko, L. (2010) · British Journal of Healthcare Assistants · doi:10.12968/bjha.2010.4.3.47063 · Cited by 2 · see citing works

In vitro anti-oxidative and carbohydrates digesting enzymes inhibitory effects of some medicinal plants used for the management of diabetes in the Mrewa district, Zimbabwe.

Chipiti, T. (2014) · ResearchSpace (University of KwaZulu-Natal) · Cited by 2 · see citing works

PHARMACOLOGICAL AND BIOLOGICAL EVALUATION OF METHANOL EXTRACTS OF SELECTED CHOLISTANI PLANTS

Sadiq, F., Habib, H., Shehzad, M. I., Fatima, K., Saeed, H., Shafique, M., Ajmal, S., Noor, T., Mustafa, M., Ashraf, H., et al. (2024) · The Journal of Animal and Plant Sciences · doi:10.36899/japs.2024.3.0743 · Cited by 1 · see citing works

Glucagon-like Peptide-1 Receptor Agonists and Platelet Function: Potential Benefits Beyond Glycemic Control

Xanthopoulou, M., Evangelidis, P., Poulis, D., Gavriilaki, E., Kotsiou, N., Antza, C., Kotsis, V., Doxani, C., Mprotsis, T., Zintzaras, E., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19030462 · Cited by 1 · see citing works

In-Silico Design of Novel Glucagon-Like Peptide 1 Mutants as Candidate for New Peptide Agonist Drugs

Sumaryada, T. I., Roslia, A. W., Afifah, A., Wahyudi, S. T., & Kartono, A. (2021) · HAYATI Journal of Biosciences · doi:10.4308/hjb.28.1.92 · Cited by 1 · see citing works

Targeting cells with cathelicidin nanomedicines improves insulin function and pancreas regeneration in type 1 diabetic rats

Cristelo, C., Nunes, R., Pinto, S. F. T., Marques, J. M., Gama, F. M., & Sarmento, B. (2023) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.1021/acsptsci.3c00218

Current treatment of type 2 diabetes

Nazarko, L. (2011) · Nursing and Residential Care · doi:10.12968/nrec.2011.13.11.530

Management of Diabetes Mellitus: Shifting Paradigm

Latif, Z. A. (2012) · Journal of Bangladesh College of Physicians and Surgeons · doi:10.3329/jbcps.v30i3.12459

Effect of metformin on global phosphorylation profiles of primary skeletal muscle cells derived from overweight/obese insulin resistant human participants

Shah, N. S. (2015) · Human Biology

Exenatide Reduces Graft Injury in a Rat Transplantation Model Using Kidneys Donated after Cardiac Death

Yang, H., Shi, Y., Long, C., Li, X., Luo, L., Chen, M., Li, H., & Wang, Z. (2019) · Transplantation Proceedings · doi:10.1016/j.transproceed.2019.04.034

BindingDB Entry 50005918: Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates.

BindingDB (2020) · UC San Diego · doi:10.7270/q2h41vdr

BindingDB Entry 50033589: Progress in structure based drug design for G protein-coupled receptors.

BindingDB (2012) · UC San Diego · doi:10.7270/q23n23rz

BindingDB Entry 50042358: Design and synthesis of diazatricyclodecane agonists of the G-protein-coupled receptor 119.

BindingDB (2013) · UC San Diego · doi:10.7270/q2bg2q91

The mechanism and clinical effects of exenatide

Ding, S., Yang, X., & Sun, F. (2012) · Intern J Endocrinol Metab · doi:10.3760/cma.j.issn.1673-4157.2012.05.011

Exenatid - ein Inkretin-Mimetikum zur Behandlung des Diabetes mellitus Typ 2

Reuter, H., & Erdmann, E. (2007) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-2007-970380 · Cited by 5 · see citing works

The incretin mimetic, exenatide: a novel treatment option for type 2 diabetes Published by:

(2014)

Exenatide,a novel incretin mimetic hormone for type 2 diabetes

Zhi-mei, X., & Nano, H. (2006) · Drug Evaluation

The incretin mimetic, exenatide: a novel treatment option for type 2 diabetes

Schnabel, C. A. (2005) · The British Journal of Diabetes · doi:10.1177/14746514050050040801 · Cited by 4 · see citing works